Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human RANKL Monoclonal Antibody

Catalog No.: YR0036

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Denosumab Biosimilar

Isotype
Human IgG2 kappa

Immunogen
Human RANK Ligand

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG2 Kappa Isotype Control Antibody

Recommended Dilution Buffer
1×PBS pH 5.2

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃